Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for Cellfx® Nspfa Cardiac Surgery System for the Treatment of Atrial Fibrillation
pulse biosciences公司宣佈其Cellfx® Nspfa心臟手術系統獲得FDA突破性設備認定,用於心房顫動的治療。
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for Cellfx® Nspfa Cardiac Surgery System for the Treatment of Atrial Fibrillation
pulse biosciences公司宣佈其Cellfx® Nspfa心臟手術系統獲得FDA突破性設備認定,用於心房顫動的治療。
譯文內容由第三人軟體翻譯。